Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P19835
UPID:
CEL_HUMAN
Alternative names:
Bile salt-stimulated lipase; Bucelipase; Carboxyl ester lipase; Cholesterol esterase; Pancreatic lysophospholipase; Sterol esterase
Alternative UPACC:
P19835; Q16398; Q5T7U7; Q9UCH1; Q9UP41
Background:
Bile salt-activated lipase (BSAL), also known as carboxyl ester lipase, plays a pivotal role in lipid metabolism by catalyzing the hydrolysis of various lipids including cholesteryl esters and phospholipids. Its ability to break down fat-soluble vitamins and dietary fats is crucial for their intestinal absorption. BSAL's alternative names, such as bile salt-stimulated lipase and pancreatic lysophospholipase, reflect its diverse enzymatic functions and its production in the pancreas.
Therapeutic significance:
BSAL's mutation is linked to Maturity-onset diabetes of the young 8 with exocrine dysfunction, a condition characterized by insulin secretion defects and pancreatic dysfunction. Understanding BSAL's role could open doors to potential therapeutic strategies for treating lipid metabolism disorders and related diabetes.